Achilles Therapeutics (NASDAQ:ACHL – Free Report) had its target price reduced by Chardan Capital from $11.00 to $6.00 in a research report released on Friday, Benzinga reports. They currently have a buy rating on the stock. Other research analysts also recently issued reports about the company. Piper Sandler reissued a neutral rating and issued a […]

Related Keywords

United States , America , Piper Sandler , Fcpm Iii Services , Blackrock Inc , Achilles Therapeutics Plc , Citadel Advisors , Renaissance Technologies , Achilles Therapeutics , Free Report , Chardan Capital , Vestal Point Capital , Get Free Report , Therapeutics Plc , Achilles Therapeutics Daily , Nasdaq Achl , Bachl , Medical , Lower Price Target ,